Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant

Erin W. Meermeier, P. Leif Bergsagel

Research output: Contribution to journalReview articlepeer-review


Multiple myeloma is a hematologic malignancy of plasma cells that manifests with bone marrow tumors causing lytic bone lesions. Autologous stem cell transplantation (ASCT) after high-dose chemotherapy and followed by prolonged maintenance therapy with lenalidomide (LEN) is an effective standard-of-care therapy for multiple myeloma. However, most patients ultimately relapse. Rational combination strategies that address immune dysfunction may prolong the durability of ASCT. In this issue of the JCI, Minnie and colleagues investigated the addition of a checkpoint inhibitor to LEN maintenance therapy after ASCT. They found that the immune checkpoint TIGIT was an optimal target in patient samples. In a syngeneic, immunocompetent multiple myeloma mouse model, blockade of TIGIT synergized with LEN maintenance by inducing immune protection, characterized in part by the expansion of polyfunctional T cells in the bone marrow. The treatment enhanced durable antimyeloma efficacy and has translatable implications.

Original languageEnglish (US)
Article numbere167346
JournalJournal of Clinical Investigation
Issue number4
StatePublished - Feb 15 2023

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'Revisiting checkpoint inhibitors for myeloma: maintenance after stem cell transplant'. Together they form a unique fingerprint.

Cite this